Vol. 14. Núm. 25.
Páginas 1501-1505 (Febrero 2025)

Protocolos de práctica asistencial
Protocolo diagnóstico y terapéutico del carcinoma de la vía biliar

Diagnostic and treatment protocol for bile duct cancer

R. Molina VillaverdeaeB. Martínez-AmoresbA. López AlfonsocA.M. Jiménez Gordod
Doi : https://10.1016/j.med.2025.01.015
Opciones
Resumen

El cáncer de las vías biliares engloba un grupo heterogéneo de neoplasias epiteliales originadas en el árbol biliar, incluida la vesícula biliar. Se considera un tipo de tumor poco frecuente en los países occidentales, aunque su incidencia ha aumentado en los últimos años. Hay distintos subgrupos anatómicos con diferencias en cuanto a factores de riesgo, presentación clínica, características moleculares y tratamientos locorregionales. La mayoría de los casos se van a diagnosticar en estadios avanzados y hasta un 80% de los tumores resecados van a recidivar, por lo que son neoplasias de mal pronóstico.

Palabras clave
Colangiocarcinoma
Carcinoma vía biliar
Carcinoma vesícula biliar
Abstract

Bile duct cancer encompasses a heterogeneous group of epithelial neoplasms originating in the biliary tree, including the gallbladder. It is considered a rare tumor in Western countries, although its incidence has increased in recent years. There are different anatomical subgroups with differences in risk factors, clinical presentation, molecular characteristics, and locoregional treatments. Most cases will be diagnosed in advanced stages and there will be recurrence in up to 80% of resected tumors, so they are neoplasms with a poor prognosis.

Keywords
Cholangiocarcinoma
Bile duct cancer
Gallbladder cancer

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
ICD-11 [Internet]
202502100823072388
. Disponible en: https://icd.who.int/en. [citado Feb 2023].
[2]
J.M. Banales
202502100823072389
2025021008230723810
, R.C. Huebert, T. Karlsen, M. Strazzabosco, N.F. LaRusso, G.J. Gores.
Cholangiocyte pathobiology.
Nat Rev Gastroenterol Hepatol., (2019), 16 pp. 269-281
[3]
J.W. Valle
2025021008230723811
2025021008230723812
, R.K. Kelley, B. Nervi, D. Oh, A.X. Zhu.
Biliary tract cancer.
[4]
A. Rizzo
2025021008230723813
, G. Brandi.
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Cancer Treat Res Commun., (2021), 27 pp. 100354
[5]
P.M. Rodrigues
2025021008230723814
2025021008230723815
, P. Olaizola, N.A. Paiva, I. Olaizola, A. Agirre-Lizaso, A. Landa, et al.
Pathogenesis of cholangiocarcinoma.
Annu Rev Pathol., (2021), 16 pp. 433-463
[6]
K. Baria
2025021008230723816
, E. De Toni, B. Yu, Z. Jiang, S. Kabadi, M. Malvezzi.
World-wide incidence and mortality of biliary tract cancer.
Gastro Hep Advances., (2022), 1 pp. 618-626
[7]
J.M. Banales
2025021008230723817
2025021008230723818
, V. Cardinale, G. Carpino, M. Marzioni, J.B. Andersen, P. Invernizzi, et al.
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Nat Rev Gastroenterol Hepatol., (2016), 13 pp. 261-280
[8]
F. Hand
2025021008230723819
, E. Hoti.
Contemporary role of liver transplantation for the treatment of cholangiocarcinoma.
Expert Rev Gastroenterol Hepatol., (2020), 14 pp. 475-481
[9]
J.N. Primrose
2025021008230723820
, R.P. Fox, D.H. Palmer, H.Z. Malik, R. Prasad, D. Mirza, et al.
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Lancet Oncol., (2019), 20 pp. 663-673
[10]
D. Oh
2025021008230723821
, A. Ruth He, S. Qin, L. Chen, T. Okusaka, A. Vogel, et al.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
NEJM Evid., (2022), 1
[11]
R.K. Kelley
2025021008230723822
, M. Ueno, C. Yoo, R.S. Finn, J. Furuse, Z. Ren, et al.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet., (2023), 401 pp. 1853-1865
[12]
A. Lamarca
2025021008230723823
, D.H. Palmer, H.S. Wasan, P.J. Ross, Y.T. Ma, A. Arora, et al.
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Lancet Oncol., (2021), 22 pp. 690-701
[13]
A. Lamarca
2025021008230723824
2025021008230723825
, J. Barriuso, M.G. McNamara, J.W. Valle.
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer.
J Hepatol., (2020), 73 pp. 170-185
[14]
G.K. Abou-Alfa
2025021008230723826
, T. Macarulla, M.M. Javle, R.K. Kelley, S.J. Lubner, J. Adeva, et al.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol., (2020), 21 pp. 796-807
[15]
G.K. Abou-Alfa
2025021008230723827
, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, et al.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol., (2020), 21 pp. 671-684